Tesamorelin Research for Visceral Fat Reduction
An evidence-based overview of research examining Tesamorelin in the context of visceral fat reduction. This page synthesizes findings from peer-reviewed literature.
Research Summary
Tesamorelin specifically targets visceral adipose tissue (VAT) - the dangerous fat around organs - while having minimal effect on subcutaneous fat. This selective action makes it unique among fat-reduction therapies and addresses a particularly harmful fat compartment.
Clinical trials consistently show 15-27 cm² reductions in VAT measured by CT imaging. The mechanism relates to differential GH receptor expression: visceral fat has high GH receptor density and lipolytic sensitivity, while subcutaneous fat is relatively resistant.
The targeting of visceral fat is clinically significant because VAT is more strongly associated with cardiovascular disease, insulin resistance, and inflammatory markers than subcutaneous fat, making the selective action therapeutically valuable.
Referenced Studies
Click any PMID to view the full study on PubMed.
Other Peptides Studied for Visceral Fat Reduction
Important Disclaimer
This page summarizes research findings and does not constitute medical advice. Tesamorelin may have regulatory approval for some indications but should only be used under qualified medical supervision. Always consult a healthcare provider before making health decisions.